If you have secondary breast cancer with a known or suspected BRCA mutation, you may be eligible to participate in a clinical trial being conducted at centres in Brisbane, Sydney, Melbourne, Ballarat, and Geelong.
The Phase 3 EMBRACA trial is testing whether a new drug, talazoparib (BMN673), will significantly extend the time to progression and overall survival of people with a BRCA1 or BRCA2 gene mutation compared with current standard-of-care single agent chemotherapy. Talazoparib belongs to the PARP inhibitor class of drugs, and is an oral medication.
Trial participants will be randomly allocated into one of two trial groups. One group will receive talazoparib and the second group what is known as “physician’s choice” chemotherapy as recommended by their medical oncologist.
This trial is for women and men with secondary breast cancer with a BRCA1 or BRCA2 gene mutation. Genetic testing will be provided free of charge to confirm you carry a BRCA mutation. Genetic counsellors are available to support you through this process.
To be eligible for the trial you must also have had no more than two previous rounds of chemotherapy for your metastatic disease, no platinum chemotherapy, no prior PARP inhibitor treatment, and not have HER2-positive breast cancer.
More information on this trial is available at the Australian New Zealand Clinical Trials Registry website, www.anzctr.org.au (type EMBRACA into the trial search field). If you are interested in the trial, you may like to discuss it with your medical oncologist.